June 20, 2014 Investing and Market Analysis Protalix Drug in Phase IIa Study for Gaucher Disease – Analyst Blog Protalix BioTherapeutics, Inc. ( PLX ) announced that it has enrolled the first patient in a 28 day open label, …read more